Interactive reveal. Use mouse or arrow keys to move the clear area around. Space or enter to expand. Escape to hide.Reveal blurred
Reveal clear

Functional Profiling of Rheumatoid Arthritis Reveals Disease-Specific Immunomodulatory Responses and Novel Therapeutic Targets

Apr 16, 2026

Boudesco et al

Now reading:

Functional Profiling of Rheumatoid Arthritis Reveals Disease-Specific Immunomodulatory Responses and Novel Therapeutic Targets

Author

Boudesco et al

Date

Apr 16, 2026

4/16/26

Today's RA therapies only slow disease. The next generation needs to cure it, and that first requires a comprehensive map of immune dysfunction, which is exactly what we're working to build.

At IMMUNOLOGY2026, Graph's co-founder and VP Immunology Christophe Boudesco presented the latest results from Graph's Functional Immune Manifold (FIM): a platform that fuses functional perturbation of patient immune cells with multi-omics data to map immune dysfunction and uncover clinically positioned, therapeutically tractable biology in immune diseases.

The crux of our work is a generalized approach that merges large-scale functional profiling with sparse transcriptomic data. By combining functional responses with existing priors, we identify context-dependent, biomarker-stratified targets - the kind built for curative intent, not chronic management.

It's a patient-first, clinically linked approach to I&I discovery. And we're quickly advancing candidates into validation.

View our full poster here

Today's RA therapies only slow disease. The next generation needs to cure it, and that first requires a comprehensive map of immune dysfunction, which is exactly what we're working to build.

At IMMUNOLOGY2026, Graph's co-founder and VP Immunology Christophe Boudesco presented the latest results from Graph's Functional Immune Manifold (FIM): a platform that fuses functional perturbation of patient immune cells with multi-omics data to map immune dysfunction and uncover clinically positioned, therapeutically tractable biology in immune diseases.

The crux of our work is a generalized approach that merges large-scale functional profiling with sparse transcriptomic data. By combining functional responses with existing priors, we identify context-dependent, biomarker-stratified targets - the kind built for curative intent, not chronic management.

It's a patient-first, clinically linked approach to I&I discovery. And we're quickly advancing candidates into validation.

View our full poster here

Copyright GraphTx 2026

Vienna, Asutria

Vienna, Austria

All system opperational